The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
The partnership initially will focus on cardiovascular and kidney diseases
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
